Arrowhead Pharmaceuticals
Biotech · Private
RNAi and TRiM (Targeted RNAi Molecule) platforms for therapeutic development
arrowheadpharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 13 granted · 27 pending
- Sector median: 2
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3067 | Synthis Therapeutics, Inc. | — | — |
| 3068 | Ottimo Pharma | — | — |
| 3069 | Vidasym, Inc | — | — |
| 3070 | Arrowhead Pharmaceuticals | — | — |
| 3071 | XTEM PHARMACEUTICALS, INC. | — | — |
| 3072 | SENEB BIOSCIENCES, INC. | — | — |
| 3073 | Roivant Sciences | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Useapplication
- RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Usegranted
- RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Useapplication
- 5'-CYCLO-PHOSPHONATE Modified Nucleotidesapplication
- Targeting Lignumsapplication
- RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Useapplication
- RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Useapplication
- Anti-transferrin Receptor Antibodies, Conjugates Thereof, And Uses Thereofapplication
- Integrin Targeting Ligands And Uses Thereofgranted
- Metabolically Stabilized Carbohydrate Targeting Ligands For Oligonucleotide Conjugatesapplication
- Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use Thereofapplication
- RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Usegranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.